Trial · NCT03393780
Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures
NCT03393780, Completed, Ferring Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures. Trials, record NCT03393780. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03393780
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures
- NCT number
- NCT03393780
- Status
- Completed
- Enrollment
- 1,018 participants, actual
- Lead sponsor
- Ferring Pharmaceuticals
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- Follitropin Delta
- First posted
- 2018-01-09
- Last updated
- 2023-02-09
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Use of algorithm-based individualised dosing regimen to decide daily dose of REKOVELLE® | At consultation visit where the daily dose of REKOVELLE® is decided | Calculated with body weight in kilograms or pounds and AMH serum level in pmoL/L or ng/ml to define the daily dose of REKOVELLE® in micrograms |
| Primary | Use of the dosing App | At consultation visit where the daily dose of REKOVELLE® is decided | Use of the Ferring developed dosing app for the daily dose calculation by answering yes/no to a questionnaire |
| Primary | Daily dose of REKOVELLE® in micrograms | From day 1 up to day 20 of REKOVELLE® stimulation | |
| Primary | Number of days of treatment with REKOVELLE® | From day 1 up to day 20 of REKOVELLE® stimulation | Adjusted during the stimulation based on blood sample of Oestrogen levels and number of follicles (at the discretion of the investigator) |
| Primary | Day of REKOVELLE® stimulation start | At the day of the first REKOVELLE® injection during the ovarian stimulation treatment | The time point of the start of the stimulation is decided at the discretion of the investigator |
| Primary | Day of REKOVELLE® stimulation end | At the day of the last REKOVELLE® injection during the ovarian stimulation treatment | The time point of the end of the stimulation is decided at the discretion of the investigator |
| Primary | Type of GnRH used for Lutenizing Hormone(LH) surge suppression | At consultation visit where the LH surge suppression protocol is decided | Defined as a choice between GnRH agonist and GnRH antagonist |
| Primary | Day of LH surge suppression protocol start | At the day of the first GnRH administration during the ovarian stimulation treatment | The time point of the start of LH surge suppression is decided at the discretion of the investigator |
| Primary | Day of LH surge suppression protocol end | At the day of the last GnRH administration during the ovarian stimulation treatment | The time point of the end of LH surge suppression is decided at the discretion of the investigator |
| Primary | Type of drug used for the triggering of follicle maturation | At consultation visit where the triggering of follicle maturation protocol is decided | Decided as a choice between hCG and/or GnRH |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36619578 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03393780
GET https://conductscience.org/api/trials/v1/NCT03393780/registered